EUVIMEDEUVIMED entdecken
Crossref

Fosfomycin (Contepo) for Complicated Urinary Tract Infections

The Medical Letter on Drugs and Therapeutics · 06.07.2026 · 68 (1758) · 107-108

DOI: 10.58347/tml.2026.1758b ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 06.07.2026.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA has approved an IV formulation of the epoxide antibacterial drug fosfomycin (Contepo – Meitheal) for treatment of adults with complicated urinary tract infections (cUTIs) caused by susceptible isolates of Escherichia coli or Klebsiella pneumoniae. Oral fosfomycin has been available in the US for years for treatment of uncomplicated urinary tract infections. IV fosfomycin has been available in other countries for decades.

Schlagwörter

Stichwörter der Autor:innen

ContepoPseudomonas aeruginosaadverse effectscefepimeceftriaxonedosagedrug interactionsefficacyfluoroquinolonesfosfomycinlactationpiperacillin/tazobactampregnancysafetyurinary tract infections

Zitieren

APA

(2026). Fosfomycin (Contepo) for Complicated Urinary Tract Infections. The Medical Letter on Drugs and Therapeutics, 68(1758), 107-108. https://doi.org/10.58347/tml.2026.1758b

Vancouver

Fosfomycin (Contepo) for Complicated Urinary Tract Infections. The Medical Letter on Drugs and Therapeutics. 2026;68(1758):107-108. doi:10.58347/tml.2026.1758b

BibTeX
@article{euvimed2026,
  title = {Fosfomycin (Contepo) for Complicated Urinary Tract Infections},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2026},
  volume = {68},
  number = {1758},
  pages = {107--108},
  doi = {10.58347/tml.2026.1758b}
}
Kostenlos starten →